CellaVision AB (publ) (CVLLY)

Market Cap	485.50M +10.7%
Revenue (ttm)	76.44M +1.9%
Net Income	13.82M -8.9%
EPS	0.29 -8.9%
Shares Out	n/a
PE Ratio	34.20
Forward PE	26.95
Dividend	0.15 (1.47%)
Ex-Dividend Date	Apr 30, 2026

Volume	100
Open	10.09
Previous Close	n/a
Day's Range	10.09 - 10.09
52-Week Range	6.30 - 10.09
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About CellaVision AB

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and Cella...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1994
• Employees: 252
• Stock Exchange: OTCMKTS
• Ticker Symbol: CVLLY

Financial Performance

In 2025, CellaVision AB's revenue was 758.97 million, an increase of 4.94% compared to the previous year's 723.22 million. Earnings were 153.08 million, an increase of 8.78%.

Financial numbers in SEK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 10, 2026

Data Sources Report a data error